Article | October 4, 2021

Achieving Cell And Gene Manufacturing Scalability: A Conversation With AVROBIO's Geoff MacKay

Source: Cytiva

By Cytiva

iStock-1268214384-cell-gene-virus

One of the greatest obstacles that gene therapy companies face is scale-up. Lentiviral gene therapies, still early in their clinical journey, also have that challenge, with companies racing to find the technologies and solutions necessary to achieve commercial success.

AVROBIO is a clinical-stage company pursuing investigational therapies in a handful of rare lysosomal disorders. Geoff MacKay, President and CEO of AVROBIO, believes we’re on the verge of innovations that will allow companies to scale transformational early-stage science into global therapeutic solutions.

“One of the elephants in the room is this: How do you take this petri dish science and mass produce pharmaceutical grade medicine?” AVRO and others are trying to tackle this problem, and it is one that MacKay says requires creativity and adaptability across every phase of development.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: